Physician profile
Michael J Versackas
NPI 1457309551
$3,274.08
in general payments reported to CMS, 2019-2025
18 companies · $891 in 2025
The $891 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $493 · 2020: $177 · 2021: $36.50 · 2022: $376 · 2023: $479 · 2024: $821 · 2025: $891.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,192.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,191.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $561.32 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Abbvie INC. | $558.44 | 2022-2025 | Durysta |
| Allergan, INC. | $452.03 | 2019-2022 | |
| Glaukos Corporation | $399.21 | 2022-2024 | Idose, Istent Trabecular Micro-Bypass System Model Is3 |
| Horizon Therapeutics Plc | $336.61 | 2023 | Tepezza |
| Tarsus Pharmaceuticals, INC. | $189.05 | 2024-2025 | Xdemvy |
| Alcon Vision LLC | $131.58 | 2025 | Precision7 |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $125.68 | 2019 | |
| Amgen INC. | $121.73 | 2024 | Tepezza |
| Sight Sciences, INC. | $100.27 | 2022 | |
| Sun Pharmaceutical Industries INC. | $95.71 | 2019-2024 | |
| Topcon Healthcare Solutions, INC. | $49.32 | 2019 | |
| Shire North American Group INC | $45.94 | 2019 | |
| Novartis Pharmaceuticals Corporation | $40.57 | 2022 | |
| New World Medical,INC. | $17.84 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $17.42 | 2024 | Tyrvaya |
| Carl Zeiss Meditec, INC. | $16.61 | 2020 | |
| Dompe US, INC. | $14.75 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Versackas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.